Prescribing for Children and Adolescents – Attention Deficit/Hyperactivity Disorder

Prescribing for Children and Adolescents – Attention Deficit/Hyperactivity Disorder

ADHD is a recognized mental condition that significantly influences the functioning of the patient and it mostly impacts attention, concentration, decision-making, and the regulation of emotions. Individuals suffering from this condition display behaviors that are developmentally unsuitable, encompassing inattentiveness, hyperactivity, and impulsiveness. This paper aims to discuss pharmacological and non-pharmacological drug recommendations for ADHD psychological condition, assess the risk assessment utilized before application, and support the proposals using the provided clinical criteria. Drug Recommendation ADHD can be effectively controlled through medication and psychological therapy, with certain symptoms potentially improving as the individual grows older. There are various FDA approved pharmacological treatment drugs available both for children and adults. These includes Adderall capsules (10mg-20mg) for children of age 3 years and above, Azstarys ( 39.2 mg serdexmethylphenidate/ 7.8mg dexmethylphenidate) daily dosage for children 6 years and above, and Concerta (18mg to 36mg) daily dosage for children 6 years and above (Research, 2023). The most frequently recommended off-label medications for youngsters include methylphenidate for age 3-5 years, Guanfacine for age 6-12 years, and Clunidine for age 12-18 years. These drugs are mostly preferred because of different reasons, such as reduced adverse effects, efficacy in managing binge episodes, many of them are FDA recommended for alternative mental disorders, accessibility, and dependability and safety in treatment approaches (Panther et al., 2018). FamilyBased Therapy (FBT) is a non-drug approach that is effective for children grappling with this